Formycon AG (FRA:FYB)
28.95
-0.65 (-2.20%)
Last updated: Jun 27, 2025
Formycon AG Employees
Formycon AG had 250 employees as of December 31, 2024. The number of employees increased by 12 or 5.04% compared to the previous year.
Employees
250
Change (1Y)
12
Growth (1Y)
5.04%
Revenue / Employee
€278,696
Profits / Employee
€502,688
Market Cap
522.64M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Rheinmetall AG | 28,539 |
Siemens Energy AG | 98,000 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Siemens Healthineers AG | 72,000 |
Formycon AG News
- 1 day ago - EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara biosimilar FYB202 (ustekinumab) under the brand name Fymskina in Germany - Wallstreet:Online
- 2 days ago - EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in the United States and Canada - Wallstreet:Online
- 3 days ago - EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period - Wallstreet:Online
- 7 days ago - EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse - Wallstreet:Online
- 9 days ago - EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities - Wallstreet:Online
- 9 days ago - EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started - Wallstreet:Online
- 10 days ago - EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets - Wallstreet:Online
- 10 days ago - EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth - Wallstreet:Online